For example, in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors, ctDNA analysis at the time of resistance can identify mechanisms of resistance such as secondary EGFR mutations and MET amplification182,184. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.